Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MPM Tries Again To Spur Early-Stage Asian Biotech Investments

This article was originally published in PharmAsia News

Executive Summary

Even though its initial early-stage investment in an Asian biotech seven years ago has seen few copies, MPM Capital of the United States is trying again. The company has invested $20 million in Sai Advantium Pharma, a contract research outfit in India. MPM had hoped to spur investments in Asian biotechs in 2001 when it invested $48 million in Taiwan's TaiGen Biotechnology, a small-molecule drug-discovery firm. Only recently did other investment companies, such as OrbiMed Advisors, follow MPM's lead. Early-stage investments in Asia remain a rarity. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts